The North America in vitro diagnostics market is expected to grow from USD 40.4 billion in 2025 to approximately USD 50.22 billion by 2035, at a CAGR of 2.20%. This growth is driven by advancements in diagnostic technologies, increasing healthcare investments, and rising demand for early disease detection and monitoring.The market growth is driven by advanced healthcare systems, high disease burden and early adoption of innovative diagnostic technologies.

North America In Vitro Diagnostics Market Statical Scope

North America In Vitro Diagnostics Market Share, By Product, 2025 (%)

• Instruments – Instruments hold a significant portion, with a share of 27%, supported by ongoing investments in advanced diagnostic equipment and technology upgrades.
• Reagents - Reagents dominate the segment, with a share of 58%, driven by their recurring usage in diagnostic tests, high testing volumes, and continuous demand across laboratories and hospitals.
• Services – Services account for a smaller share, with a share of 15%, driven by growing outsourcing of diagnostic testing and lab management services.

North America In Vitro Diagnostics Market Share, By Technology, 2025 (%)

• Immunoassay - Immunoassay leads the segment, with a share of 26%, driven by its widespread use in disease detection, high sensitivity, and broad application range.
• Hematology - Hematology accounts for a steady share, with a share of 14%, supported by routine blood analysis and diagnostic screening.
• Clinical Chemistry - Clinical Chemistry holds a notable share, with a share of 18%, supported by routine diagnostic testing and high throughput in laboratories.

North America In Vitro Diagnostics Market Share, By Application, 2025 (%)

• Infectious Diseases - Infectious Diseases lead the segment, with a share of 24%, driven by high testing demand for viral and bacterial infections and ongoing public health monitoring.
• Diabetes - Diabetes holds a significant portion, with a share of 17%, supported by the rising prevalence of diabetes and need for continuous monitoring.
• Oncology - Oncology accounts for a notable share, with a share of 14%, driven by increasing cancer cases and demand for early detection and monitoring.

North America In Vitro Diagnostics Market Share, By Test Location, 2025 (%)

• Point of Care - Point of Care holds a significant portion, with a share of 36%, supported by demand for rapid diagnostics and immediate results in clinical settings.
• Home-care - Home-care accounts for a smaller share, with a share of 14%, driven by increasing adoption of at-home diagnostic testing solutions.

North America In Vitro Diagnostics Market Share, By End Use, 2025 (%)

• Hospitals – Hospitals lead the segment, with a share of 42%, driven by high patient inflow and extensive use of diagnostic testing in inpatient and emergency care.
• Laboratory - Laboratories hold a significant portion, with a share of 33%, supported by specialized diagnostic services and high testing throughput.

Top Companies in the North America In Vitro Diagnostics Market

• Abbott
• Bio-Rad Laboratories, Inc
• Siemens Healthineers AG
• BIOMÉRIEUX
• BD
• QIAGEN
• Quidel Corporation
• F. Hoffmann-La Roche Ltd.
• Danaher
• Quest Diagnostics Incorporated
• Agilent Technologies, Inc.

Segments Covered in the Report

By Product

• Instruments
• Reagents
• Services

By Technology

• Immunoassay
• Hematology
• Clinical Chemistry
• Molecular Diagnostics
• Coagulation
• Microbiology
• Others

By Application

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Other applications

By Test Location

• Point of Care
• Home-care
• Services

By End Use

• Hospitals
• Laboratory
• Home Care
• Others